Allosensitization after transplant failure: the role of graft nephrectomy and immunosuppression - a retrospective study.


Journal

Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516

Informations de publication

Date de publication:
09 2019
Historique:
received: 22 11 2018
revised: 07 01 2019
accepted: 09 04 2019
pubmed: 14 4 2019
medline: 1 4 2020
entrez: 14 4 2019
Statut: ppublish

Résumé

There are conflicting data about the role of transplant nephrectomy and immunosuppression withdrawal on the development of allosensitization and the impact on re-transplantation. We divided 109 first graft recipients into two groups according to whether they underwent nephrectomy (NX+, n = 61) or their graft was left in situ (NX-, n = 48). Sera were assessed for HLA-A/B/Cw/DR/DQ antibodies at the time of NX/transplant failure and after 3, 6, 12, 24 months. The NX+ group showed a higher rate of donor specific antibody (DSA) and non-DSA human leukocyte antigen (HLA) antibody production at all the time points. Multivariable analysis showed that nephrectomy was a strong, independent risk factor for the development of DSAs after 12 and 24 months (P = 0.005 and 0.008). In the NX- group, low tacrolimus levels correlated with DSA formation (AUC 0.817, P = 0.002; best cut-off level 2.9 ng/ml). Analysis with a standardized pool of UK donors showed a more difficult grade of HLA matchability following nephrectomy compared with the NX- group. Nephrectomy is followed by the long-term production of DSA and non-DSA HLA antibodies and negatively impacts on the chances of finding a HLA-compatible kidney. Tacrolimus levels ≥3 ng/ml are protective against the development of allosensitization and could facilitate re-transplantation in the NX- group.

Identifiants

pubmed: 30980556
doi: 10.1111/tri.13442
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Histocompatibility Antigens Class II 0
Immunosuppressive Agents 0
Tacrolimus WM0HAQ4WNM

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

949-959

Informations de copyright

© 2019 Steunstichting ESOT.

Références

Assfalg V, Huser N, van Meel M, et al. High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. Nephrol Dial Transplant 2016; 31: 1515.
Langone AJ, Chuang P. The management of the failed renal allograft: an enigma with potential consequences. Semin Dial 2005; 18: 185.
Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2: 970.
Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
Ojo A, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. Transplantation 1998; 66: 1651.
Bostock IC, Alberu J, Arvizu A, et al. Probability of deceased donor kidney transplantation based on % PRA. Transpl Immunol 2013; 28: 154.
Perasaari JP, Kyllonen LE, Salmela KT, Merenmies JM. Pre-transplant donor-specific anti-human leukocyte antigen antibodies are associated with high risk of delayed graft function after renal transplantation. Nephrol Dial Transplant 2016; 31: 672.
Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324.
Billen EV, Christiaans MH, Lee J, van den Berg-Loonen EM. Donor-directed HLA antibodies before and after transplantectomy detected by the luminex single antigen assay. Transplantation 2009; 87: 563.
Del Bello A, Congy-Jolivet N, Sallusto F, et al. Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol 2012; 7: 1310.
Augustine JJ, Woodside KJ, Padiyar A, Sanchez EQ, Hricik DE, Schulak JA. Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure. Transplantation 2012; 94: 738.
Lachmann N, Schonemann C, El-Awar N, et al. Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy. Nephrol Dial Transplant 2016; 31: 1351.
Del Bello A, Congy-Jolivet N, Kamar N. Maintaining immunosuppressive treatment after early allograft nephrectomy does not reduce the risk of anti-HLA allosensitization. Transpl Int 2015; 28: 1113.
Wang K, Xu X, Fan M, Qianfeng Z. Allograft nephrectomy vs. no-allograft nephrectomy for renal transplantation: a meta-analysis. Clin Transplant 2016; 30: 33.
Szatmary P, Jones J, Hammad A, Middleton D. Impact of sensitivity of human leucocyte antigen antibody detection by Luminex technology on graft loss at 1 year. Clin Kidney J 2013; 6: 283.
Del Bello A, Congy N, Sallusto F, et al. Anti-human leukocyte antigen immunization after early allograft nephrectomy. Transplantation 2012; 93: 936.
Redfield RR, Scalea JR, Zens TJ, et al. The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients. Nephrol Dial Transplant 2016; 31: 1746.
Hung SY, Lin TM, Chang MY, et al. Risk factors of sensitization to human leukocyte antigen in end-stage renal disease patients. Hum Immunol 2014; 75: 531.
Evans RW, Manninen DL, Dong FB, McLynne DA. Is retransplantation cost effective? Transpl Proc 1993; 25: 1694.
Sapir-Pichhadze R, Tinckam KJ, Laupacis A, Logan AG, Beyene J, Kim SJ. Immune sensitization and mortality in wait-listed kidney transplant candidates. J Am Soc Nephrol 2016; 27: 570.
Zachary AA, Leffell MS. HLA mismatching strategies for solid organ transplantation - a balancing act. Front Immunol 2016; 7: 575.
Lenaers J, Christiaans M, van Heurn E, van Hooff H, van den Berg-Loonen E. Frequent but late donor-directed antibody formation after kidney transplantectomy within one month after grafting. Transplantation 2006; 81: 614.
Milongo D, Kamar N, Del Bello A, et al. Allelic and epitopic characterization of intra-kidney allograft anti-HLA antibodies at allograft nephrectomy. Am J Transplant 2017; 17: 420.
Bayliss GP, Gohh RY, Morrissey PE, Rodrigue JR, Mandelbrot DA. Immunosuppression after renal allograft failure: a survey of US practices. Clin Transplant 2013; 27: 895.
Smak Gregoor PJ, Zietse R, van Saase JL, et al. Immunosuppression should be stopped in patients with renal allograft failure. Clin Transplant 2001; 15: 397.
Woodside KJ, Schirm ZW, Noon KA, et al. Fever, infection, and rejection after kidney transplant failure. Transplantation 2014; 97: 648.
Lopez-Gomez JM, Perez-Flores I, Jofre R, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15: 2494.
Casey MJ, Wen X, Kayler LK, Aiyer R, Scornik JC, Meier-Kriesche HU. Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. Transplantation 2014; 98: 306.
Perl J, Bargman JM, Davies SJ, Jassal SV. Clinical outcomes after failed renal transplantation-does dialysis modality matter? Semin Dial 2008; 21: 239.
Lin J, Wang R, Xu Y, Chen J. Impact of renal allograft nephrectomy on graft and patient survival following retransplantation: a systematic review and meta-analysis. Nephrol Dial Transplant 2018; 33: 700.
Matignon M, Leibler C, Moranne O, et al. Anti-HLA sensitization after kidney allograft nephrectomy: changes one year post-surgery and beneficial effect of intravenous immunoglobulin. Clin Transplant 2016; 30: 731.

Auteurs

Gaetano Lucisano (G)

Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, UK.

Paul Brookes (P)

Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, UK.

Eva Santos-Nunez (E)

Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, UK.

Nicola Firmin (N)

Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, UK.

Nicola Gunby (N)

Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, UK.

Sevda Hassan (S)

Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, UK.

Alexander Gueret-Wardle (A)

Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, UK.

Paul Herbert (P)

Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, UK.

Vassilios Papalois (V)

Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, UK.

Michelle Willicombe (M)

Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, UK.

David Taube (D)

Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH